Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
This Non-Interventional Study will describe and analyze the clinical use of pyrotinib in clinical practice in the treatment of HER2 positive breast cancer in the real world.
HER2-positive Breast Cancer
OTHER: non-interventional
Progression Free Survival(PFS), Progression Free Survival(PFS), 12 months|Pathological Complete Response（pCR）Rate, Percentage of Participants With Pathological Complete Response, through study completion, an average of 1 year|Incidences of adverse events and toxicities, Incidences of adverse events and toxicities, through study completion, an average of 1 year
This Non-Interventional Study will describe and analyze the clinical use of pyrotinib in clinical practice in the treatment of HER2 positive breast cancer in the real world.